Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Express Scripts Hopes To Refine Risk Level Under Medicare Rx

This article was originally published in The Pink Sheet Daily

Executive Summary

Express Scripts is hopeful that the Medicare Rx implementing regs can be refined to have a manageable level of risk, CEO Barrett Toan told analysts July 29

You may also be interested in...



Medco Will Work With CMS On Medicare Rules: Backpedaling From "Fallback"?

Medco has been asked by CMS to offer constructive ideas to help make private drug insurance work, and company says it intends to do that in commenting on Part D regulations. However, CEO suggests Medco remains most interested in working under Medicare Advantage and through "fallback" plan.

Medicare Rx Implementing Regs Open For Comment Until October

Proposed rules for Title I (Part D drug benefit) and Title II (Medicare Advantage) of the Medicare Modernization Act are unveiled at an HHS press conference. Final regs will be done by early 2005, "if not sooner," CMS Administrator McClellan says.

U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says

The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.

Topics

UsernamePublicRestriction

Register

PS060171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel